Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping

Award Number: R01AT013147
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/15/2025
PERIOD OF PERFORMANCE END DATE: 01/31/2030

Group Awards By:

View Award Description

Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping - PROJECT SUMMARY/ABSTRACT Dietary flavonoid ingestion has been linked with a reduction in cardiovascular events. We previously made the serendipitous finding that a specific class of flavonoid quercetins inhibits protein disulfide isomerase (PDI). PDI is an oxidoreductase that is important for protein folding in the endoplasmic reticulum. However, when released into the extracellular environment, PDI promotes thrombus formation. Over the past decade, we studied the use of flavonoid quercetins to target PDI in the context of thrombosis. Our experiments have spanned atomic resolution studies evaluating structural elements of the flavonoid-PDI interactions to cell-based assays to preclinical models to human studies. Recognizing the unmet need to develop an antithrombotic agent that is well tolerated and does not increase the risk of hemorrhage, we focused the clinical development of isoquercetin in patients with cancer at high risk for developing venous thromboembolism. We previously conducted a phase 2 trial in patients with advanced cancer and observed a significant reduction in circulating plasma D-dimer consistent with antithrombotic activity. However, before proceeding with a definitive phase 3 trial, we acknowledge critical gaps in the data package. Importantly, based on recent pharmacodynamic modeling, we remain uncertain of the optimal dosing schedule, as we currently believe that isoquercetin 1000 mg twice daily is preferred rather than the previous phase 2 dosing schedule of 1000 mg once daily. We also identified different prothrombotic mechanisms specifically in cancer, which we believe can identify patients with cancer who are likely to benefit most from primary thromboprophylaxis with isoquercetin. Our aims in this study are 1) to determine the optimal isoquercetin dosing based on target PDI inhibition utilizing a PDI-sensitive thrombin generation assay in patients with ovarian cancer, a group particularly at risk for thrombosis; and 2) to identify which hypercoagulable phenotypes of cancer are most amenable to PDI inhibition, and thus aiming to tailor treatment more effectively and advance a personalized approach to thromboprophylaxis in cancer care. In summary, this study seeks not only to refine isoquercetin therapeutic dosing schedule but also explore function- activity relationships of isoquercetin in specific hypercoagulable contexts, thereby enabling a phase 3 trial to develop a more targeted, safe, and effective approach toward prevention of cancer-associated thrombosis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $612,382 )
2026	2026	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Research and Training in Complementary and Integrative Health	000	2	3/10/2026	NON-COMPETING CONTINUATION	$612,382
														Subtotal = $612,382

Issue Date FY: 2025 ( Subtotal = $631,382 )
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Research and Training in Complementary and Integrative Health	001	1	6/26/2025	NEW	$0
2025	2025	SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH	1275 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Research and Training in Complementary and Integrative Health	000	1	4/10/2025	NEW	$631,382
														Subtotal = $631,382

Grand Total All Awards = $1,243,764

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Isoquercetin as a PDI inhibitor: dose-optimization and patient phenotyping

Award Number: R01AT013147

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/15/2025

PERIOD OF PERFORMANCE END DATE: 01/31/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer